Christopher A Lipinski

US Patent:

8552184, Oct 8, 2013

Filed:

Jul 1, 2009

Appl. No.:

12/495857

Inventors:

Andrew G. Reaume - Exton PA, US
Michael S. Saporito - Exton PA, US
Alexander R. Ochman - Exton PA, US
Christopher K. Lipinski - Waterford CT, US

Assignee:

Melior Pharmaceuticals I, Inc. - Exton PA

International Classification:

C07D 239/06
C07D 239/02
A61K 31/505

US Classification:

544302, 544314, 514274

Abstract:

The present invention relates to compounds and pharmaceutically acceptable salts thereof, and compositions comprising the same, that are useful in modulating lyn kinase activity, treating obesity, type II diabetes, metabolic syndrome, and in reducing blood glucose level, weight gain, or fat depot level, or treating a disease or condition associated with the same.

US Patent:

44529872, Jun 5, 1984

Filed:

Dec 13, 1982

Appl. No.:

6/449129

Inventors:

John L. LaMattina - Ledyard CT
Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D23364

US Classification:

548343

Abstract:

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H. sub. 2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

US Patent:

45902992, May 20, 1986

Filed:

Feb 11, 1985

Appl. No.:

6/700370

Inventors:

John L. LaMattina - Ledyard CT
Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07C 49227

US Classification:

568415

Abstract:

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H. sub. 2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

US Patent:

43024645, Nov 24, 1981

Filed:

Oct 16, 1980

Appl. No.:

6/197388

Inventors:

John L. LaMattina - Ledyard CT
Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 3144
C07D40104

US Classification:

424263

Abstract:

A series of 2-substituted-4-(4-imidazolyl)pyridines and the pharmaceutically acceptable acid addition salts thereof as histamine H. sub. 2 -receptor inhibitors for controlling gastric acidity.

US Patent:

45103135, Apr 9, 1985

Filed:

Mar 27, 1984

Appl. No.:

6/593791

Inventors:

John L. LaMattina - Ledyard CT
Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D27748

US Classification:

548194

Abstract:

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H. sub. 2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

US Patent:

45755078, Mar 11, 1986

Filed:

May 29, 1985

Appl. No.:

6/738924

Inventors:

Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31415
C07D47110
C07D49107
C07D23378

US Classification:

514278

Abstract:

Compounds related to 3',4'-dihydrospiro[imidazolidine-4,1'(2'H)-naphthalene]2,3',5-trione, spiro[chroman-4,4'-imidazolidine]2,2',5'-trione and 1',2'-dihydrospiro[imidazolidine-4,4'-(3'H)-quinoline 2,2'5-trione and reduced products thereof as aldose reductase inhibitors.

US Patent:

39418898, Mar 2, 1976

Filed:

Nov 4, 1974

Appl. No.:

5/520486

Inventors:

Christopher Andrew Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31505

US Classification:

424251

Abstract:

The preparation of novel 5-(substituted phenoxy)-4-amino and substituted amino pyrimidines is described. These compounds, possessing anti-secretory and anti-ulcer activity, are effective anti-ulcer agents.

US Patent:

42762979, Jun 30, 1981

Filed:

Jun 18, 1979

Appl. No.:

6/049737

Inventors:

Christopher A. Lipinski - Waterford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 3144
C07D40104

US Classification:

424263

Abstract:

A series of novel 3-amino-5-(4-pyridyl)-1,2,4-triazole derivatives has been prepared, including their pharmaceutically acceptable acid addition salts. These particular compounds are useful in therapy as anti-ulcer agents. Preferred member compounds include 3-amino-5-[2-(N-monomethylamino)-4-pyridyl]-1,2,4-triazole, 3-amino-5-[2-(N-monoethylamino)-4-pyridyl]-1,2,4-triazole and 3-amino-5-[2-(N,N-dimethylamino)-4-pyridyl]-1,2,4-triazole. Alternate methods of preparation are provided and the principal synthetic routes leading to the preferred compounds are described in some detail.